Avosentan

Known as: 2-Pyridinesulfonamide, N-(6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl)-5-methyl-, 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2016
02420062016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Multiple studies indicate that endothelin antagonism may have a protective effect for chronic kidney disease. Despite that… (More)
Is this relevant?
2012
2012
Several clinical studies have investigated the potential benefits of endothelin receptor antagonism in chronic pathologies such… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
PURPOSE To investigate the vasoactive effect of ET(A)-endothelin receptor antagonists avosentan (SPP-301) and BQ-123 in isolated… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
In the short term, the endothelin antagonist avosentan reduces proteinuria, but whether this translates to protection from… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2010
2010
When Yanagisawa et al.1 first identified endothelin (ET), a novel polypeptide vasoconstrictor for which numerous other functions… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Despite the first-line use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), there is… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
In the present study, we evaluated the effect of simultaneously blocking angiotensin II synthesis and endothelin (ET)-1 activity… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2009
2009
There is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular disease. This… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2009
2009
The endothelin receptor antagonist avosentan may cause fluid overload at doses of 25 and 50 mg, but the actual mechanisms of this… (More)
Is this relevant?
2009
2009
OBJECTIVE Avosentan is a potent, selective endothelin A receptor blocker. The pharmacokinetics of avosentan were investigated in… (More)
Is this relevant?